Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

TP ICAP mulls Wall Street debut for data unit

(Sharecast News) - Broker TP ICAP said on Tuesday that it is mulling a New York listing for its data business, with the debut potentially happening as early as the second quarter. The City stalwart said it was considering various options for Parameta Solutions, but the focus was listing a minority stake in the US.

Nicolas Breteau, chief executive, said: "Should we proceed - with no certainty we will do so - the listing could occur as early as the second quarter.

"Our priority is to create sustainable shareholder value and retain, for the long term, the majority of any upside potential, while providing Parameta with a greater ability to grow on a standalone basis."

The listing would be a blow the London market, which is struggling to attract flotations. TP ICAP - which was formed by City veteran Michael Spencer - said the US "has the deepest, most liquid public markets" and was home to a number of Parameta's quoted peers as well as more research analysts.

Around 93% of Parameta's revenues are US dollar denominated.

The update came as TP ICAP posted numbers for the year to December end. They showed a 3% uplift in revenues - or 5% on a constant currency basis - to £2.25bn, while earnings before interest, tax, depreciation and amortisation jumped 7% to £398m.

Earnings before interest and tax were up 8% at £324m.

Breteau said: "We delivered record profits in 2024. All divisions traded well, underling the power of our diversified business and the continued delivery of our strategy."

Looking to the current year, TP ICAP noted: "Geopolitical tension, and the uncertain outlook for trade policies, inflation, as well as interest rate movements, should continue to drive volatility that is supportive for our business.

"Subject to movements in foreign exchange rates, the board is comfortable with current market expectations for adjusted EBIT."

Consensus is currently for around £345m.

Shore Capital, which has a 'buy' rating on the FTSE 250 stock, said the results "read well, with P&L metrics ahead of consensus forecasts".

It continued: "Despite recent share price strength, forecast momentum is likely to be positive in the near term after a strong set of results and what we surmise to be good trading conditions for the core business.

"Moreover, partial disposal of Parameta, which is now looking imminent, could unlock significant incremental value."

As at 1015 GMT, shares in TP ICAP were nearly 1% lower at 257.5p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.